| EXAMINATION | - SABEEN LULU ET AL, "Humoral-Targeted Immunotherapies in Multiple Sclerosis", NEUROTHERAPEUTICS, US, (20130101), vol. 10, no. 1, doi:10.1007/s13311-012-0164-3, ISSN 1933-7213, pages 34 - 43, XP055333733 | |
| EXAMINATION | - ONTANEDA DANIEL ET AL, "Progressive multiple sclerosis", CURRENT OPINION IN NEUROLOGY, RAPID SCIENCE PUBLISHERS, LONDON, GB, (20150601), vol. 28, no. 3, doi:10.1097/WCO.0000000000000195, ISSN 1350-7540, pages 237 - 243, XP009192987 | |
| EXAMINATION | - ZHANG JIAMENG ET AL, "EDSS variability before randomization may limit treatment discovery in primary progressive MS", MULTIPLE SCLEROSIS JOURNAL, US, vol. 19, no. 6, doi:10.1177/1352458512459685, ISSN 1352-4585, (20130501), pages 775 - 781, URL: https://journals.sagepub.com/doi/pdf/10.1177/1352458512459685, XP055841737 | |
| EXAMINATION | - ROMMER PAULUS S ET AL, "Rituximab for secondary progressive multiple sclerosis: a case series", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, (20110629), vol. 25, no. 7, doi:10.2165/11589390-000000000-00000, ISSN 1172-7047, pages 607 - 613, XP008157975 | |
| OPPOSITION | - Anonymous, "761053Orig1s000 MEDICAL REVIEW(S): Ocrevus/ocrelizumab ; Reference ID: 3987680", MEDICAL REVIEW(S), FDA; CENTER FOR DRUG EVALUATION AND RESEARCH, pages 1 - 477, MEDICAL REVIEW(S), URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053orig1s000medr.pdf, XP093309820 | - |
| OPPOSITION | - Anonymous, "Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study", Genentech: Press Releases, Genentech, Inc., pages 1 - 4, Genentech: Press Releases, URL: https://www.gene.com/media/press-releases/14608/2015-09-27/genentechs-ocrelizumab-first-investigati, XP093311060 | - |
| OPPOSITION | - Anonymous, "Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis", Genentech: Press Releases, Genentech, Inc., pages 1 - 6, Genentech: Press Releases, URL: https://www.gene.com/media/press-releases/14609/2015-10-08/genentechs-ocrelizumab-first-investigati, XP093311079 | - |
| OPPOSITION | - Anonymous, "Genentech's Ocrelizumab First lnvestigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase Ill Study", Pipeline Review, La Merie Publishing, DE, DE, pages 1 - 6, Pipeline Review, URL: https://pipelinereview.com/genentech-s-ocrelizumab-first-investigation-Medicine-to-Show-Efficacy-in-People-with-Primary-Progressive-Multiple-Sclerosis-in-Large-Phase-Ill-Study.htm, XP093311519 | - |
| OPPOSITION | - Anonymous, "News from the ECTRIMS Annual Meeting: Ocrelizumab Reported t... : Neurology Today", NeurologyToday, pages 1 - 7, NeurologyToday, URL: https://journals.lww.com/neurotodayonline/fulltext/2015/11050/news_from_the_ectrims_annual_meeting__ocrelizumab.6.aspx, XP093311712 | - |
| OPPOSITION | - Anonymous, "Roche's ocrelizumab first investigational medicine to show efficacy in people with primary progressive multiple sclerosis in large Phase III study", Press Release, Fierce Pharma, pages 1 - 3, Press Release, URL: https://www.fiercepharma.com/marketing/roche-s-ocrelizumab-first-investigational-medicine-to-show-efficacy-people-primary, XP093309801 | - |
| OPPOSITION | - D13 - Reply of Patentee in opposition case EP 3 747 464 B1 (20 176 370.3), submitted on 7 Auqust 2025 | - |
| OPPOSITION | - D1 - Declaration by Prof Hemmer) with Exhibits 1-11 | - |
| OPPOSITION | - D40a - Wayback machine entries for D18 during September 2015. Available at: https://web.archive.org/web/*/https://seekingalpha.com/article/3353505-roche-holdings-rhhby-ceo-severin-schwan-on-q2-2015-results-earnings-call-transcript* | - |
| OPPOSITION | - D40c - Roic AI, Roche Holdings Inc. Q2 2015 Earnings Conference Call on 23 July 2015. Available at: https://www.roic.ai/quote/RHHBY/transcripts/2015-year/2-quarter | - |
| OPPOSITION | - F Hoffmann, Roche Ltd -La, "Media Release: Roche’s ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis ", Media Release, F. Hoffmann-La Roche Ltd, Basel, CH, Basel, CH, (20151008), Media Release, URL: https://assets.roche.com/imported/en/med-cor-2015-10-08-e.pdf, (20170111), XP055334454 | - |
| OPPOSITION | - Genentech, Inc., "Genentech: Press Releases | Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years", URL: http://www.gene.com/media/press-releases/13627/2011-10-19/phase-ii-study-showed-ocrelizumab-mainta, (20150717), XP055203108 | - |
| OPPOSITION | - Hauser, S L, Gc Comi, H-P Hartung, K Selmaj, A Traboulsee, A Bar-Or, Dl Arnold, G Klingelschmitt, F Lublin, H Garren, L Kappos, "Efficacy and Safety of Ocrelizumab in Relapsing Multiple Sclerosis - Results of the Phase III Double-blind, Interferon beta-1a-controlled OPERA I and II Studies", 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2015; 7 - 10 October 2015 - Barcelona - Spain, (20151019), pages 1 - 22, XP093311077 | - |
| OPPOSITION | - Hawker Kathleen; O'Connor Paul; Freedman Mark; Calabresi Peter; Antel Jack; Simon Jack; Hauser Stephen; Waubant Emmanuelle; Vollmer Timothy; Paniteh Hillel; Zhang Jia-meng; Chin Peter; Smith Craig H, "Efficacy and Safety of Rituximab in Patients with Primary Progressive Multiple Sclerosis (PPMS): Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial", Neurology, Lippincott Williams & Wilkins, (20090301), vol. 72, no. 11, Suppl. 3, ISSN 0028-3878, page A254, XP009128823 | - |
| OPPOSITION | - Helwick Caroline, "Ocrelizumab benefit in PPMS consistent in subgroups - Consortium of Multiple Sclerosis Centers", MSCare.org, pages 1 - 7, MSCare.org, URL: https://www.mscare.org/ocrelizumab-benefit-in-ppms-consistent-in-subgroups/, XP093311709 | - |
| OPPOSITION | - Helwick Caroline, "Ocrelizumab Benefit in Primary Progressive MS Consistent in Subgroups", MedScape, pages 1 - 2, MedScape, URL: https://www.medscape.com/viewarticle/859222, XP093311706 | - |
| OPPOSITION | - Hoffmann-La Roche, "NCT01194570 | A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis ", ClinicalTrials.gov, NLM, pages 1 - 26, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT01194570?tab=history&a=96#version-content-panel, XP093311160 | - |
| OPPOSITION | - Kurtzke J. F., Ludwig Kappos, "Neurostatus Scoring: Definitions for a standardised, quantified neurological examination and assessment of Kurtzke's Functional Systems and Expanded Disability Status Scale in Multiple Sclerosis Slightly modified from", Neurostatus Scoring, Neurostatus.Net, pages 1 - 11, Neurostatus Scoring, URL: https://www.neurostatus.net/media/specimen/Definitions_0410-2_s.pdf, XP093311059 | - |
| OPPOSITION | - Maia, Margarida, "Disability progression in PPMS Anti-CD20 therapies appear to be ineffective in real-world study", Multiple Sclerosis, News Today, pages 1 - 4, Multiple Sclerosis, News Today, URL: https://multiplesclerosisnewstoday.com/news-posts/2024/10/02/ocrevus-rituximab-ineffective-disability-progression-ppms/, XP093269112 | - |
| OPPOSITION | - Montalban X, B Hemmer, K Rammohan, G Giovannoni, J De Seze, A Bar-Or, Dl Arnold, A Sauter, D Masterman, P Chin, H Garren, J Wolinsky, "Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis - Results of the Phase III, Double-blind, Placebo-controlled ORATORIO Study", 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2015; 7 - 10 October 2015 - Barcelona - Spain, (20151019), pages 1 - 19, XP093311078 | - |
| OPPOSITION | - Palkhivala Alison, "Rituximab Effective Only in Selected Patients With Primary Progressive Multiple Sclerosis", MedScape, pages 1 - 2, MedScape, URL: https://www.medscape.com/viewarticle/580869_print, XP093269108 | - |
| OPPOSITION | - Preston David C, "Magnetic Resonance Imaging (MRI) of the Brain and Spine: Basics", Magnetic Resonance Imaging (MRI) of the Brain and Spine, Case Western Reserve University, pages 1 - 5, Magnetic Resonance Imaging (MRI) of the Brain and Spine, URL: https://case.edu/med/neurology/NR/MRI%20Basics.htm, XP093311725 | - |
| OPPOSITION | - Roche Hoffmann-La, "NCT01194570 | A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis ", ClinicalTrials.gov, NLM, pages 1 - 26, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT01194570?tab=history&a=105#version-content-panel, XP093309798 | - |
| OPPOSITION | - Roche Products Limited, "OCREVUS 300 mg concentrate for solution for infusion", Summary of Product Characteristics (SmPC), Medicines.org.uk, pages 1 - 17, Summary of Product Characteristics (SmPC), URL: https://www.medicines.org.uk/emc/product/8898/smpc/print, XP093311466 | - |
| OPPOSITION | - Roche Products Limited, "Ocrevus 920 mg solution for injection", Summary of Product Characteristics (SmPC), Medicines.org.uk, pages 1 - 17, Summary of Product Characteristics (SmPC), URL: https://www.medicines.org.uk/emc/product/15824/smpc/print, XP093311467 | - |
| OPPOSITION | - Sa Transcripts, "Roche Holding's (RHHBY) CEO Severin Schwan on Q2 2015 Results - Earnings Call Transcript", Seeking Alpha, (20150907), pages 1 - 23, Seeking Alpha, URL: https://web.archive.org/web/20150907011207/http://seekingalpha.com/article/3353505-roche-holdings-rhhby-ceo-severin-schwan-on-q2-2015-results-earnings-call-transcript, XP093311157 | - |
| OPPOSITION | - Sa Transcripts, "Roche Holding's (RHHBY) CEO Severin Schwan on Q2 2015 Results - Earnings Call Transcript | Seeking Alpha", Seeking Alpha, pages 1 - 40, Seeking Alpha, URL: https://seekingalpha.com/article/3353505-roche-holdings-rhhby-ceo-severin-schwan-on-q2-2015-results-earnings-call-transcript, XP093311151 | - |
| OPPOSITION | - Simon Jack H, Li D, Traboulsee A, Coyle P K, Arnold D L, Barkhof F, Frank J A, Grossman R, Paty D W, Radue E W, Wolinsky J S, "Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines", American Journal of Neuroradiology, US , (20060201), vol. 27, no. 2, ISSN 0195-6108, pages 455 - 461, XP093268740 | - |
| OPPOSITION | - Virginia Meca-Lallana, X. Montalban, B. Hemmer, K. Rammohan, G. Giovannoni, J. De Seze, A. Bar-Or, D.L. Arnold, A. Sauter, A. Kakarieka, D. Masterman, P. Chin, H. Garren, J. Wolinsky, "Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study at 31ST CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS 2015; 7 - 10 OCTOBER 2015 - BARCELONA - SPAIN", URL: https://learn.ectrims.eu/ectrims/2015/31st/116701/virginia.mecalallana.efficacy.and.safety.of.ocrelizumab.in.primary.html?f=menu%3D14%2Abrowseby%3DX7%2Asortby%3D2%2Aspeaker%3DX130729, XP093311097 | - |
| OPPOSITION | - Waubant E, "Spotlight on Anti-CD20", INTERNATIONAL MS JOURNAL, CAMBRIDGE MEDICAL PUBLISHERS, WORTHING, GB, GB , (20080101), vol. 15, no. 1, ISSN 1352-8963, pages 19 - 25, XP093269105 | - |
| OPPOSITION | - Wolinsky J, Dl Arnold, A Bar-Or, J De Seze, G Giovannoni, B Hemmer, K Rammohan,P Chin, P Fontoura, H Garren, D Masterman, A Sauter, X Montalban , "Ocrelizumab Efficacy in PPMS Patients in the Presence/Absence of T1 Gadolinium-Enhancing Lesions at Baseline in a Phase III Placebo-Controlled Trial; Oral Presentation DX06", The 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers National Harbor, MD, USA, June 1-4, 2016, (20160608), pages 1 - 6, XP093311129 | - |
| OPPOSITION | - Wolinsky Jerry, Dl Arnold, A Bar-Or, J De Seze, G Giovannoni, B Hemmer, K Rammohan,P Chin, P Fontoura, H Garren, D Masterman, A Sauter, "Abstract: Ocrelizumab Efficacy in PPMS Patients in the Presence/Absence of T1 Gadolinium-Enhancing Lesions at Baseline in a Phase III, Placebo-Controlled Trial (2016 CMSC Annual Meeting)", THE 2016 ANNUAL MEETING OF THE CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS NATIONAL HARBOR, MD, USA, JUNE 1-4, 2016, (20160603), pages 1 - 2, XP093311130 | - |
| OPPOSITION | - Chris H. Polman; Stephen C. Reingold; Gilles Edan; Massimo Filippi; Hans‐Peter Hartung; Ludwig Kappos; Fred D. Lublin; Luanne M. Metz; Henry F. McFarland; Paul W. O'Connor; Magnhild Sandberg‐Wollheim; Alan J. Thompson; Brian G. Weinshenker; Jerry S. Wolinsky, "Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”", Annals of Neurology, John Wiley and Sons, Boston , US, Boston , US , (20051110), vol. 58, no. 6, doi:10.1002/ana.20703, ISSN 0364-5134, pages 840 - 846, XP071637904 | |
| OPPOSITION | - Amit Bar‐Or; Peter A. J. Calabresi; Douglas Arnold; Clyde Markowitz; Stuart Shafer; Lloyd H. Kasper; Emmanuelle Waubant; Suzanne Gazda; Robert J. Fox; Michael Panzara; Neena Sarkar; Sunil Agarwal; Craig H. Smith, "Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial", Annals of Neurology, John Wiley and Sons, Boston , US, Boston , US , (20080326), vol. 63, no. 3, doi:10.1002/ana.21363, ISSN 0364-5134, pages 395 - 400, XP071638579 | |
| OPPOSITION | - Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H. Smith, "Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial", Annals of Neurology, John Wiley and Sons, Boston , US, Boston , US , (20090909), vol. 66, no. 4, doi:10.1002/ana.21867, ISSN 0364-5134, pages 460 - 471, XP071639199 | |
| OPPOSITION | - Hans‐Peter Hartung; Orhan Aktas, "Bleak prospects for primary progressive multiple sclerosis therapy: Downs and downs, but a glimmer of hope", Annals of Neurology, John Wiley and Sons, Boston , US, Boston , US , (20090925), vol. 66, no. 4, doi:10.1002/ana.21880, ISSN 0364-5134, pages 429 - 432, XP071639195 | |
| OPPOSITION | - Mark C. Genovese, Jeffrey L. Kaine, Mitchell B. Lowenstein, José Del Giudice, Andrew Baldassare, Joy Schechtman, Edward Fudman, Michael Kohen, Sheila Gujrathi, Robert G. Trapp, Nadera J. Sweiss, Greg Spaniolo, Wolfgang Dummer, "Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study", Arthritis & Rheumatism, Wiley InterScience, US, US , (20080901), vol. 58, no. 9, doi:10.1002/art.23732, ISSN 0004-3591, pages 2652 - 2661, XP055190940 | |
| OPPOSITION | - Rigby W., Tony H.‐p., Oelke K., Combe B., Laster A., Von Muhlen C. A., Fisheleva E., Martin C., Travers H., Dummer W., "Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty‐eight-week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial", Arthritis & Rheumatism, Wiley InterScience, US, US , (20120201), vol. 64, no. 2, doi:10.1002/art.33317, ISSN 0004-3591, pages 350 - 359, XP093311134 | |
| OPPOSITION | - Mysler Eduardo F., Spindler Alberto J., Guzman Renato, Bijl Marc, Jayne David, Furie Richard A., Houssiau Frédéric A., Drappa Jorn, Close David, Maciuca Romeo, Rao Kajal, Shahdad Saba, Brunetta Paul, "Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study", Arthritis & Rheumatism, Wiley InterScience, US, US , (20130901), vol. 65, no. 9, doi:10.1002/art.38037, ISSN 0004-3591, pages 2368 - 2379, XP093311141 | |
| OPPOSITION | - Sabeen Lulu, Emmanuelle Waubant, "Humoral-Targeted Immunotherapies in Multiple Sclerosis", Neurotherapeutics, Springer International Publishing, Cham, Cham, (20130101), vol. 10, no. 1, doi:10.1007/s13311-012-0164-3, ISSN 1933-7213, pages 34 - 43, XP055333733 | |
| OPPOSITION | - M Yin, Hoff F, Roche Ltd Mann-La, Basel Switzerland ( D, Leppert R, Glanzman J, Tinbergen, Kappos Prof Ludwig, "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20111119), vol. 378, no. 9805, doi:10.1016/S0140-6736(11)61649-8, pages 1779 - 1787, XP055333854 | |
| OPPOSITION | - Wolinsky Jerry S; Arnold Douglas L; Brochet Bruno; Hartung Hans-Peter; Montalban Xavier; Naismith Robert T; Manfrini Marianna; Overell James; Koendgen Harold; Sauter Annette; Bennett Iain; Hubeaux Stanislas; Kappos Ludwig; Hauser Stephen L, "Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial", The Lancet Neurology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20201029), vol. 19, no. 12, doi:10.1016/S1474-4422(20)30342-2, ISSN 1474-4422, pages 998 - 1009, XP086349456 | |
| OPPOSITION | - Caravan P, Ellison J J, McMurry T J, Lauffer R B, "GADOLINIUM(III) CHELATES AS MRI CONTRAST AGENTS: STRUCTURE, DYNAMICS, AND APPLICATIONS", Chemical Reviews, (19990820), vol. 99, no. 9, doi:10.1021/cr980440x, ISSN 0009-2665, pages 2293 - 2352, XP002375825 | |
| OPPOSITION | - Fyfe Ian, "Ocrelizumab excites ECTRIMS", Nature Reviews Neurology, Nature Publishing Group UK, London, London, (20151103), vol. 11, no. 12, doi:10.1038/nrneurol.2015.210, ISSN 1759-4758, pages 667 - 667, XP038246400 | |
| OPPOSITION | - Ciccarelli Olga, Miller David, "Magnetic Resonance Imaging in Multiple Sclerosis", Practical neurology, BMJ publishing, London, UK, London, UK , (20020401), vol. 2, no. 2, doi:10.1046/j.1474-7766.2002.00405.x, ISSN 1474-7758, pages 103 - 112, XP009562790 | |
| OPPOSITION | - Stephen L Hauser, Emmanuelle Waubant, Douglas L Arnold, Timothy Vollmer, Jack Antel, Robert J Fox, Amit Bar-Or, Michael Panzara, Neena Sarkar, Sunil Agarwal, Annette Langer-Gould, Craig H Smith, "B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis", New England Journal of Medicine, United States, (20080214), vol. 358, no. 7, doi:10.1056/NEJMoa0706383, ISSN 0028-4793, pages 676 - 688, XP002567454 | |
| OPPOSITION | - Xavier Montalban, "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis", New England Journal of Medicine, Massachusetts Medical Society, United States, United States, (20170119), vol. 376, no. 3, doi:10.1056/NEJMoa1606468, ISSN 0028-4793, pages 209 - 220, XP093166692 | |
| OPPOSITION | - J. L. Jones, J. M. Anderson, C.-L. Phuah, E. J. Fox, K. Selmaj, D. Margolin, S. L. Lake, J. Palmer, S. J. Thompson, A. Wilkins, D. J. Webber, D. A. Compston, A. J. Coles, "Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity", Brain, Oxford University Press, GB, GB , (20100801), vol. 133, no. 8, doi:10.1093/brain/awq176, ISSN 0006-8950, pages 2232 - 2247, XP055334857 | |
| OPPOSITION | - Siddharama Pawate, Bagnato Francesca, "Newer Agents in the Treatment of Multiple Sclerosis", NEUROLOGIST, WLLIAMS AND WILKINS, BALTIMORE, MD, US, US , (20150401), vol. 19, no. 4, doi:10.1097/NRL.0000000000000020, ISSN 1074-7931, pages 104 - 117, XP055333727 | |
| OPPOSITION | - Ontaneda Daniel; Fox Robert J, "Progressive multiple sclerosis", CURRENT OPINION IN NEUROLOGY, GB , (20150601), vol. 28, no. 3, doi:10.1097/WCO.0000000000000195, ISSN 1350-7540, pages 237 - 243, XP009192987 | |
| OPPOSITION | - Von Büdingen H.-Christian, Palanichamy Arumugam, Lehmann-Horn Klaus, Michel Brady A., Zamvil Scott S., "Author manuscript Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets: ", European Neurology, S. Karger AG, Switzerland, Switzerland , (20150401), vol. 73, no. 3-4, doi:10.1159/000377675, ISSN 0014-3022, pages 1 - 17, XP093311064 | |
| OPPOSITION | - Kieseier Bernd C., Pozzilli Carlo, "Assessing walking disability in multiple sclerosis", Multiple Sclerosis Journal, Sage, US, US , (20120701), vol. 18, no. 7, doi:10.1177/1352458512444498, ISSN 1352-4585, pages 914 - 924, XP093311125 | |
| OPPOSITION | - Zhang Jiameng, Waubant Emmanuelle, Cutter Gary, Wolinsky Jerry S, Glanzman Robert, "EDSS variability before randomization may limit treatment discovery in primary progressive MS", Multiple Sclerosis Journal, Sage, US, US , (20130501), vol. 19, no. 6, doi:10.1177/1352458512459685, ISSN 1352-4585, pages 775 - 781, XP055841737 | |
| OPPOSITION | - Montalban X, B. Hemmer, K. Rammohan, G. Giovannoni, J. De Seze, A. Bar-Or, D.L. Arnold, A. Sauter, A. Kakarieka, D. Masterman, P. Chin, H. Garren, J. Wolinsky, "228: Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study", Multiple Sclerosis Journal, Sage, US, US , (20150901), vol. 21, no. S11, doi:10.1177/1352458515604791, ISSN 1352-4585, pages 781 - 782, XP093311492 | |
| OPPOSITION | - Rovira Àlex, Auger Cristina, Alonso Juli, "Magnetic resonance monitoring of lesion evolution in multiple sclerosis", THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS MAY 2010, (20130901), vol. 6, no. 5, doi:10.1177/1756285613484079, ISSN 1756-2864, pages 298 - 310, XP093311121 | |
| OPPOSITION | - Mitchell E. Reff , Kristin Carner , Karen S. Chambers , Paul C. Chinn , John E. Leonard , Ron Raab , Roland A. Newman , Nabil Hanna , Darrell R. Anderson, "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19940115), vol. 83., no. 2, doi:10.1182/blood.V83.2.435.435, ISSN 0006-4971, pages 435 - 445, XP002112549 | |
| OPPOSITION | - Blüml Stephan, Mckeever Kathleen, Ettinger Rachel, Smolen Josef, Herbst Ronald, "B-cell targeted therapeutics in clinical development", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, GB , (20130301), vol. 15, no. S1, doi:10.1186/ar3906, ISSN 1478-6354, pages 1 - 21, XP093311066 | |
| OPPOSITION | - Motl Robert, Neal Whitney, Backus Deborah, Hebert Jeffrey, Mccully Kevin, Bethoux Francois, Plummer Prudence, Ng Alexander, Lowman John, Schmidt Hollie, Mcburney Robert, Cutter Gary, "Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosis", BMC NEUROLOGY, BIOMED CENTRAL LTD., LONDON, GB, GB , (20241010), vol. 24, no. 1, doi:10.1186/s12883-024-03871-1, ISSN 1471-2377, pages 383 - 8, XP093309806 | |
| OPPOSITION | - Hay Marion, Rollot Fabien, Casey Romain, Kerbrat Anne, Edan Gilles, Mathey Guillaume, Labauge Pierre, De Sèze Jérôme, Vukusic Sandra, Laplaud David-Axel, Papeix Caroline, Moreau Thibault, Thouvenot Eric, Defer Gilles, Lebrun-Frénay Christine, Ciron Jonathan, Berger Eric, Stankoff Bruno, Clavelou Pierre, Maillart Elisabeth, Heinzlef Olivier, Zéphir Hélène, Ruet Aurélie, Casez Olivier, Moulin Solène, Al-Khedr Abdullatif, Bourre Bertrand, Pelletier Jean, Magy Laurent, Neau Jean-Philippe, Camdessanché Jean-Philippe, Doghri Inès, Wahab Abir, Tchikviladzé Maia, Labeyrie Céline, Hankiewicz Karolina, Le Page Emmanuelle, Michel Laure, "Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis : A Multicenter Real-Life Study", Neurology, Lippincott Williams & Wilkins, (20241022), vol. 103, no. 8, doi:10.1212/WNL.0000000000209886, ISSN 0028-3878, pages 1 - 13, XP093269111 | |
| OPPOSITION | - Chris H. Polman, Rudick, Richard A., "The Multiple Sclerosis Functional Composite - A clinically meaningful measure of disability", Neurology, Lippincott Williams & Wilkins, (20100427), vol. 74, no. Suppl. 3, doi:10.1212/WNL.0b013e3181dbb571, ISSN 0028-3878, pages S8 - S17, XP055071466 | |
| OPPOSITION | - KURTZKE J F, "RATING NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AN EXPANDED DISABILITY STATUS SCALE", Neurology, Lippincott Williams & Wilkins, (19830101), vol. 33, no. 11, doi:10.1212/WNL.33.11.1444, ISSN 0028-3878, pages 1444 - 1452, XP009186641 | |
| OPPOSITION | - Montalban Xavier, Hemmer Bernhard, Rammohan Kottil, Giovannoni Gavin, De Seze Jerome, Bar-Or Amit, Arnold Douglas, Sauter Annette, Leppert David, Chin Peter, Garren Hideki, Wolinsky Jerry, "Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017)", Neurology, Lippincott Williams & Wilkins, (20150406), vol. 84, no. 14_supplement, doi:10.1212/WNL.84.14_supplement.P7.017, ISSN 0028-3878, page P7.017, XP093311063 | |
| OPPOSITION | - Castillo-Trivino Tamara, Braithwaite Dejana, Bacchetti Peter, Waubant Emmanuelle, "Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review", PLOS ONE, Public Library of Science, US, US , (20130702), vol. 8, no. 7, doi:10.1371/journal.pone.0066308, ISSN 1932-6203, pages e66308 - 8, XP093311070 | |
| OPPOSITION | - T. Ziemssen, Et Al., "Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review", PLOS ONE, Public Library of Science, US, US , (20150922), vol. 10, no. 9, doi:10.1371/journal.pone.0138243, ISSN 1932-6203, page e0138243, XP055549863 | |
| OPPOSITION | - Buttmann Mathias; Rieckmann Peter, "Treating multiple sclerosis with monoclonal antibodies.", Expert review of neurotherapeutics, Informa UK Ltd, UK, UK , (20080301), vol. 8, no. 3, doi:10.1586/14737175.8.3.433, ISSN 1744-8360, pages 433 - 455, XP009186339 | |
| OPPOSITION | - Palavra Filipe, "Monoclonal Antibodies for Multiple Sclerosis Treatment [Anticorpos Monoclonais para Tratamento da Esclerose Múltipla]", ACTA MEDICA PORTUGUESA, Ordem dos Medicos, PT, PT , (20150901), vol. 28, no. 5, doi:10.20344/amp.6486, ISSN 0870-399X, pages 640 - 651, XP093311486 | |
| OPPOSITION | - Rommer Paulus S; Patejdl Robert; Winkelmann Alexander; Benecke Reiner; Zettl Uwe K, "Rituximab for secondary progressive multiple sclerosis: a case series.", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, AUCKLAND, NZ , (20110629), vol. 25, no. 7, doi:10.2165/11589390-000000000-00000, ISSN 1172-7047, pages 607 - 613, XP008157975 | |
| OPPOSITION | - Loleit Verena; Biberacher Viola; Hemmer Bernhard, "Current and future therapies targeting the immune system in multiple sclerosis.", Current pharmaceutical biotechnology, Netherlands, Netherlands , vol. 15, no. 3, doi:10.2174/1389201015666140617104332, ISSN 1873-4316, pages 276 - 296, XP008178154 | |
| OPPOSITION | - Chan Andrew, Schutte Albert Jan, "Interview: Experiences Targeting B Cells for the Treatment of Multiple Sclerosis", Immunotherapy, Future Medicine, London, (20140201), vol. 6, no. 2, doi:10.2217/imt.13.164, ISSN 1750-743X, pages 127 - 130, XP093311081 | |
| OPPOSITION | - Brancati Serena, Gozzo Lucia, Longo Laura, Vitale Daniela Cristina, Drago Filippo, "Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?", Frontiers in Immunology, Frontiers Media, Lausanne, CH, Lausanne, CH , (20210706), vol. 12, doi:10.3389/fimmu.2021.661882, ISSN 1664-3224, pages 661882 - 22, XP093309795 | |
| OPPOSITION | - Christian Klein, Alfred Lammens, Wolfgang Schäfer, Guy Georges, Manfred Schwaiger, Ekkehard Mössner, Karl-Peter Hopfner, Pablo Umaña, Gerhard Niederfellner, "Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties", mAbs, Landes Bioscience, US, US , (20130101), vol. 5, no. 1, doi:10.4161/mabs.22771, ISSN 1942-0862, pages 22 - 33, XP055117097 | |
